Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Issue 1 (1st November 2016)
- Record Type:
- Journal Article
- Title:
- Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Issue 1 (1st November 2016)
- Main Title:
- Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling
- Authors:
- Chen, Huanjun
Cong, Qifei
Du, Zhenyun
Liao, Wenfeng
Zhang, Lei
Yao, Yanli
Ding, Kan - Abstract:
- Highlights: FP08S2, a sulfated fucoidan, inhibited the tube formation, migration and invasion of HMEC-1 cells in vitro . This polysaccharide interfered with the interaction of VEGF with VEGFR2 to exert anti-angiogenetic effect. VEGFR2/Erk/VEGF signaling pathway was blocked by FP08S2 in HMEC-1 cells. Furthermore, FP08S2 suppressed angiogenesis and tumor growth in vivo in A549 lung cancer xenograft model. This study indicated that FP08S2 could be an anti-angiogenic candidate agent for lung cancer therapy. Abstract: Fucoidan may inhibit angiogenesis. However, its functional target molecule and the underlying mechanism are still vague. In the present study, we showed that sulfated fucoidan FP08S2 from Sargassum fusiforme inhibited tube formation as well as migration and invasion of human microvascular endothelial cells (HMEC-1). In addition, FP08S2 was confirmed to disrupt VEGF-induced angiogenesis both in vitro and in vivo . Further study indicated that FP08S2 could bind to both VEGF and VEGFR2 to interfere with VEGF–VEGFR2 interaction. Moreover, VEGFR2/Erk/VEGF signaling pathway was blocked by FP08S2 in HMEC-1 cells. Importantly, FP08S2 impeded the growth and microvessel formation of A549 cancer cell xenograft in nude mice. These results suggested that FP08S2 presented remarkable anti-angiogenic activity via blocking VEGF signaling and could be a potential novel leading compound to inhibit lung cancer cell growth.
- Is Part Of:
- Cancer letters. Volume 382:Issue 1(2016)
- Journal:
- Cancer letters
- Issue:
- Volume 382:Issue 1(2016)
- Issue Display:
- Volume 382, Issue 1 (2016)
- Year:
- 2016
- Volume:
- 382
- Issue:
- 1
- Issue Sort Value:
- 2016-0382-0001-0000
- Page Start:
- 44
- Page End:
- 52
- Publication Date:
- 2016-11-01
- Subjects:
- Fucoidan -- Angiogenesis -- VEGF -- Lung cancer
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03043835/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.canlet.2016.08.020 ↗
- Languages:
- English
- ISSNs:
- 0304-3835
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.485000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 419.xml